Epicrispr Biotechnologies
epicrispr.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$158M
2 rounds on record
Latest round
$90M
Series C · Aug 2026 · 1 mo ago
Team
201-500
employees, estimated range
Backers
1
Angelini Ventures
The money's age
Fresh money
1 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 11
Raised a round Series C $90M · YahooFinance
Mar 24
Recognition Epicrispr Biotechnologies Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 · epicrispr.com
May 12, 2025
Recognition Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize · epicrispr.com
Apr 23, 2025
Partnership Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study · epicrispr.com
Mar 30, 2025
Raised a round Series B $68M · Pulse 2.0
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series C | Aug 2026 | $90M | — | YahooFinance |
| Series B | Mar 2025 | $68M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Angelini Ventures Similar startupsby what they do, their industry and backers
Talus Bio makes the regulome—the control layer of gene expression—visible, measuring and modulating gene regulators in live cells to access…
Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that…
Kater is a data workflow builder that combines a unified data model with SQL to dynamically generate personalized reports and guide your…
Draupnir Bio is developing new innovative therapies for patients.
AI-powered gene expression models predict human tissue responses to drugs. De-risk clinical trials, optimize patient selection, and…
TamLabs — agent teams for complex work. Agent teams for complex work.
News
Daniel Hart, PhD, on CRISPR-Mediated In Vivo Epigenomic Activation CGTlive
The Senior Director and Head of Technology Development at Epic Bio discussed potential applications of the new technology.
Read more
Report
Alexandra Collin de l'Hortet, PhD, on Evaluating Epigenetic Gene Therapy for the Treatment of FSHD CGTlive
The head of therapeutics at Epic Bio discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
Read more
Report
Epicrispr Biotechnologies Raises $90 Million Series C To Advance Epigenetic Therapy EPI-321
Epicrispr Biotechnologies has closed an oversubscribed $90 million Series C financing to advance EPI-321 toward pivotal clinical development for facioscapulohumeral muscular dystrophy, or FSHD.
Read more
Report
Epicrispr raises $90m Series C to advance FSHD therapy
Epicrispr secures funding to support clinical development of EPI-321, a gene therapy targeting muscular dystrophy treatment
Read more
Report
Pro access
Upgrade to see all 36 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.